Go to home page - PHARMAC - Pharmaceutical Management Agency
Leading Edge Medicines Management home
Patients & Consumers Health Professionals District Health Boards Pharmaceutical Suppliers

Fri May 25 2012 NZST

RSSRSS feed (help and list of feeds)

<< Health Professionals

Notification

Search for previous notification documents

Page updated on 24 May 2012

Linked documents

page1

Listing azithromycin suspension; Contact: Notifications; Posted: 2012-05-24 (2 pages, 108 KB)
24 May 2012 Listing of azithromycin suspension PHARMAC is pleased to announce the listing of azithromycin suspension for the treatment and prophylaxis of pertussis in patients under one year of age. The effect of the decision is that:  Zithromax…

text


page1

Review of Dispensing Frequency for Monthly Medicines approved; Contact: Notifications; Posted: 2012-05-21 (4 pages, 119 KB)
21 May 2012 Review of Dispensing Frequency for Monthly Medicines approved PHARMAC is pleased to announce the approval of a proposal to include a number of pharmaceuticals on the ‘stat’ dispensing list. This was the subject of a consultation letter…

text


page1

Prasugrel in Stent Thrombosis patients; Contact: Notifications; Posted: 2012-05-17 (1 page, 75 KB)
17 May 2012 Prasugrel funding approved for stent thrombosis patients PHARMAC is pleased to announce the approval of a proposal to widen access to prasugrel from 1 June 2012 for patients who experience cardiac stent thrombosis whilst on clopidogrel. This…

text


page1

Approval of proposal for parecoxib; Contact: Notifications; Posted: 2012-05-15 (1 page, 99 KB)
15 May 2012 Approval of proposal to list parecoxib PHARMAC is pleased to announce approval of the proposal to list the hospital medicine parecoxib sodium 40 mg powder for injection (Dynastat) in Part II of Section H of the Pharmaceutical…

text


page1

April Tender Notification - Correction; Contact: Notifications; Posted: 2012-05-01 (1 page, 94 KB)
1 May 2012 TENDER RESULT CORRECTION – CABERGOLINE TABLETS On 30 April 2012, we notified a number of decisions relating to the 2010/11 and 2011/12 Invitation to Tender. The notification contained an error relating to cabergoline tablets. The notification should…

text


page1

April Tender Notification; Contact: Notifications; Posted: 2012-04-30 (7 pages, 134 KB)
30 April 2012 TENDER RESULTS The PHARMAC Board (or Acting Chief Executive under Delegated Authority) has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated…

text


page1

Approval of proposal to amend restrictions relating to various ophthalmology products; Contact: Notifications; Posted: 2012-04-18 (3 pages, 150 KB)
18 April 2012 Proposal to amend restrictions relating to various ophthalmology products approved PHARMAC is pleased to announce the approval of proposals to remove the prescribing guidelines for glaucoma preparations and to include several ophthalmology products on the ‘stat’ dispensing…

text


page1

Listing propylthiouracil on the Pharmaceutical Schedule; Contact: Notifications; Posted: 2012-04-17 (2 pages, 78 KB)
17 April 2012 Listing propylthiouracil on the Pharmaceutical Schedule PHARMAC is pleased to announce approval of the proposal to fund propylthiouracil (PTU) through an agreement with AFT Pharmaceuticals Ltd. This was the subject of a consultation letter dated 28 March…

text


page1

Widening access to dornase alfa; Contact: Notifications; Posted: 2012-04-17 (3 pages, 124 KB)
17 April 2012 Widening access to dornase alfa PHARMAC is pleased to announce the approval of the proposal to widen access to dornase alfa for the treatment of cystic fibrosis patients. This was the subject of a consultation letter dated…

text


page1

Approval of proposal to amend the Special Authority criteria applying to sunitinib; Contact: Notifications; Posted: 2012-04-10 (2 pages, 113 KB)
10 April 2012 Approval of proposal to amend the Special Authority criteria applying to sunitinib PHARMAC is pleased to announce approval of the proposal to amend the Special Authority criteria applying to sunitinib cap 12.5 mg, 25 mg and 50…

text


page1

March Tender Notification - correction; Contact: Notifications; Posted: 2012-04-02 (2 pages, 98 KB)
2 April 2012 TENDER RESULT CORRECTION – TESTOSTERONE UNDECANOATE On 30 March 2012, we notified a number of decisions relating to the 2011/12 Invitation to Tender. The notification contained an error relating to testosterone undecanoate capsules. The current subsidy and…

text


page1

Nutritional products (Special Foods) supplied by Nutricia; Contact: Notifications; Posted: 2012-04-02 (5 pages, 127 KB)
2 April 2012 Nutritional products (Special Foods) supplied by Nutricia PHARMAC is pleased to announce the funding of a number of nutritional products (Special Foods) supplied by Nutricia. These products will be funded from 1 April 2012 and were the…

text


page1

March Tender Notification; Contact: Notifications; Posted: 2012-03-30 (12 pages, 149 KB)
30 March 2012 TENDER RESULTS The PHARMAC Board (or Acting Chief Executive under Delegated Authority) has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2011/12 Invitation to Tender, dated…

text


page1

Mid month listing for salbutamol and doxorubicin; Contact: Notifications; Posted: 2012-03-29 (2 pages, 154 KB)
FACSIMILE To Fax From Subject All New Zealand Pharmacies, IPA Pharmacy Facilitators and Wholesalers Autodial Rebecca Bloor, Schedule Analyst Listing of  salbutamol oral liquid 2 mg per 5 ml  doxorubicin inj 50 mg Cefaclor stock issues 29 March…

text


page1

Approval of proposal to list prasugrel for clopidogrel-allergic patients; Contact: Notifications; Posted: 2012-03-19 (2 pages, 117 KB)
19 March 2012 Prasugrel listing approved for clopidogrel-allergic patients PHARMAC is pleased to announce the approval of an agreement with Eli Lilly and Company (NZ) Limited. This was the subject of a consultation letter dated 20 February 2012. In summary,…

text


page1

Approval of proposal for pazopanib, lapatinib and trastuzumab; Contact: Notifications; Posted: 2012-03-01 (7 pages, 165 KB)
1 March 2012 Approval of proposal to fund pazopanib, lapatinib and amend the Special Authority criteria applying to trastuzumab PHARMAC is pleased to announce approval of the proposal to fund pazopanib (Votrient) and lapatinib (Tykerb) and amend the Special Authority…

text


page1

February Tender Notification; Contact: Notifications (5 pages, 118 KB)
29 February 2012 TENDER RESULTS The PHARMAC Board (or Acting Chief Executive under Delegated Authority) has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2011/12 Invitation to Tender, dated…

text


page1

Approval of proposal to fully fund Symbicort Turbuhalers and Vannair; Contact: Notifications (2 pages, 109 KB)
17 February 2012 Approval of the proposal to fully fund Symbicort Turbuhalers and Vannair PHARMAC is pleased to announce the approval of an agreement with AstraZeneca Limited regarding Symbicort Turbuhaler and Vannair. This proposal was the subject of a consultation…

text


page1

Approval of proposal to widen access to ursodeoxycholic acid; Contact: Notifications (2 pages, 105 KB)
16 February 2012 Approval of proposal to widen access to ursodeoxycholic acid PHARMAC is pleased to announce the approval of a proposal to widen funded access to ursodeoxycholic acid for prevention of veno-occlusive disease in patients receiving high dose conditioning…

text


page1

January Tender Notification; Contact: Notifications (2 pages, 101 KB)
31 January 2012 TENDER RESULTS The PHARMAC Board (or Acting Chief Executive under Delegated Authority) has resolved to award a tender for Sole Subsidised Supply Status for a product included in the 2010/11 Invitation to Tender, dated 2 November 2010.…

text